Company intelligence / Profile preview

CytoHub, Inc.

La Jolla / San Diego, California, United Statescytohub.com ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

CytoHub is pioneering the use of artificial intelligence to develop advanced cell therapies for cardiac regeneration. Their platform leverages human mini-heart technology to enable drug screening, disease modeling, and the development of regenerative treatments targeting heart muscle repair. The company is focused on optimizing manufacturing processes to ensure high-quality therapeutic products but has not yet reported clinical trial results.[1][2][3][4][5]

Therapeutic areas: Cardiovascular
Modalities: Cell therapies (regenerative cell-based therapeutics)AI-driven human mini-heart technology[5]
Industry: Biotech

Partnerships

None publicly disclosed as of May 2024; open call for investors and partners[2]

Beyond the preview

Go deeper on CytoHub, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CytoHub, Inc..

Explore the full profile